vs

Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and ZILLOW GROUP, INC. (ZG). Click either name above to swap in a different company.

Amneal Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($722.5M vs $654.0M, roughly 1.1× ZILLOW GROUP, INC.). Amneal Pharmaceuticals, Inc. runs the higher net margin — 10.8% vs 0.5%, a 10.3% gap on every dollar of revenue. On growth, ZILLOW GROUP, INC. posted the faster year-over-year revenue change (18.1% vs 3.9%). Over the past eight quarters, ZILLOW GROUP, INC.'s revenue compounded faster (11.2% CAGR vs 1.5%).

Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.

Zillow Group, Inc., or simply Zillow, is an American tech real-estate marketplace company that was founded in 2006 by co-executive chairmen Rich Barton and Lloyd Frink, former Microsoft executives and founders of Microsoft spin-off Expedia; Spencer Rascoff, a co-founder of Hotwire.com; David Beitel, Zillow's current chief technology officer; and Kristin Acker, Zillow's current technology leadership advisor.

AMRX vs ZG — Head-to-Head

Bigger by revenue
AMRX
AMRX
1.1× larger
AMRX
$722.5M
$654.0M
ZG
Growing faster (revenue YoY)
ZG
ZG
+14.2% gap
ZG
18.1%
3.9%
AMRX
Higher net margin
AMRX
AMRX
10.3% more per $
AMRX
10.8%
0.5%
ZG
Faster 2-yr revenue CAGR
ZG
ZG
Annualised
ZG
11.2%
1.5%
AMRX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMRX
AMRX
ZG
ZG
Revenue
$722.5M
$654.0M
Net Profit
$78.0M
$3.0M
Gross Margin
44.3%
72.8%
Operating Margin
19.6%
-1.7%
Net Margin
10.8%
0.5%
Revenue YoY
3.9%
18.1%
Net Profit YoY
410.5%
105.8%
EPS (diluted)
$0.19
$0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMRX
AMRX
ZG
ZG
Q1 26
$722.5M
Q4 25
$814.3M
$654.0M
Q3 25
$784.5M
$676.0M
Q2 25
$724.5M
$655.0M
Q1 25
$695.4M
$598.0M
Q4 24
$730.5M
$554.0M
Q3 24
$702.5M
$581.0M
Q2 24
$701.8M
$572.0M
Net Profit
AMRX
AMRX
ZG
ZG
Q1 26
$78.0M
Q4 25
$35.1M
$3.0M
Q3 25
$2.4M
$10.0M
Q2 25
$22.4M
$2.0M
Q1 25
$12.2M
$8.0M
Q4 24
$-31.1M
$-52.0M
Q3 24
$-156.0K
$-20.0M
Q2 24
$6.0M
$-17.0M
Gross Margin
AMRX
AMRX
ZG
ZG
Q1 26
44.3%
Q4 25
36.5%
72.8%
Q3 25
34.9%
72.6%
Q2 25
39.5%
74.7%
Q1 25
36.8%
76.8%
Q4 24
36.0%
75.8%
Q3 24
38.4%
75.9%
Q2 24
35.6%
77.3%
Operating Margin
AMRX
AMRX
ZG
ZG
Q1 26
19.6%
Q4 25
13.8%
-1.7%
Q3 25
9.0%
-0.4%
Q2 25
15.4%
-1.7%
Q1 25
14.4%
-1.5%
Q4 24
10.4%
-12.5%
Q3 24
12.6%
-7.7%
Q2 24
13.6%
-6.6%
Net Margin
AMRX
AMRX
ZG
ZG
Q1 26
10.8%
Q4 25
4.3%
0.5%
Q3 25
0.3%
1.5%
Q2 25
3.1%
0.3%
Q1 25
1.8%
1.3%
Q4 24
-4.3%
-9.4%
Q3 24
-0.0%
-3.4%
Q2 24
0.9%
-3.0%
EPS (diluted)
AMRX
AMRX
ZG
ZG
Q1 26
$0.19
Q4 25
$0.10
$0.01
Q3 25
$0.01
$0.04
Q2 25
$0.07
$0.01
Q1 25
$0.04
$0.03
Q4 24
$-0.10
$-0.23
Q3 24
$0.00
$-0.08
Q2 24
$0.02
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMRX
AMRX
ZG
ZG
Cash + ST InvestmentsLiquidity on hand
$197.7M
$768.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$4.9B
Total Assets
$3.5B
$5.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMRX
AMRX
ZG
ZG
Q1 26
$197.7M
Q4 25
$282.0M
$768.0M
Q3 25
$201.2M
$874.0M
Q2 25
$71.5M
$587.0M
Q1 25
$59.2M
$914.0M
Q4 24
$110.6M
$1.1B
Q3 24
$74.0M
$1.1B
Q2 24
$43.8M
$1.2B
Total Debt
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
$2.6B
Q3 25
$2.6B
Q2 25
$2.2B
Q1 25
$2.2B
Q4 24
$2.4B
Q3 24
$2.4B
Q2 24
$2.4B
Stockholders' Equity
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
$-70.8M
$4.9B
Q3 25
$-109.5M
$5.0B
Q2 25
$-112.1M
$4.7B
Q1 25
$-131.7M
$4.8B
Q4 24
$-109.3M
$4.8B
Q3 24
$-93.4M
$4.7B
Q2 24
$-57.5M
$4.5B
Total Assets
AMRX
AMRX
ZG
ZG
Q1 26
$3.5B
Q4 25
$3.7B
$5.7B
Q3 25
$3.6B
$5.7B
Q2 25
$3.4B
$5.4B
Q1 25
$3.4B
$5.7B
Q4 24
$3.5B
$5.8B
Q3 24
$3.5B
$6.2B
Q2 24
$3.5B
$6.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMRX
AMRX
ZG
ZG
Operating Cash FlowLast quarter
$72.0M
Free Cash FlowOCF − Capex
$44.0M
FCF MarginFCF / Revenue
6.7%
Capex IntensityCapex / Revenue
4.3%
Cash ConversionOCF / Net Profit
24.00×
TTM Free Cash FlowTrailing 4 quarters
$235.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
$130.3M
$72.0M
Q3 25
$118.5M
$105.0M
Q2 25
$83.8M
$87.0M
Q1 25
$7.4M
$104.0M
Q4 24
$118.1M
$122.0M
Q3 24
$141.8M
$171.0M
Q2 24
$39.7M
$55.0M
Free Cash Flow
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
$108.5M
$44.0M
Q3 25
$106.2M
$73.0M
Q2 25
$61.0M
$50.0M
Q1 25
$-5.8M
$68.0M
Q4 24
$102.9M
$88.0M
Q3 24
$124.8M
$138.0M
Q2 24
$29.0M
$18.0M
FCF Margin
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
13.3%
6.7%
Q3 25
13.5%
10.8%
Q2 25
8.4%
7.6%
Q1 25
-0.8%
11.4%
Q4 24
14.1%
15.9%
Q3 24
17.8%
23.8%
Q2 24
4.1%
3.1%
Capex Intensity
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
2.7%
4.3%
Q3 25
1.6%
4.7%
Q2 25
3.2%
5.6%
Q1 25
1.9%
6.0%
Q4 24
2.1%
6.1%
Q3 24
2.4%
5.7%
Q2 24
1.5%
6.5%
Cash Conversion
AMRX
AMRX
ZG
ZG
Q1 26
Q4 25
3.72×
24.00×
Q3 25
50.00×
10.50×
Q2 25
3.74×
43.50×
Q1 25
0.61×
13.00×
Q4 24
Q3 24
Q2 24
6.62×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AMRX
AMRX

Segment breakdown not available.

ZG
ZG

Residential Revenue$418.0M64%
Rental Revenue$168.0M26%
Mortgage Revenue$57.0M9%
Display Advertising And Other Revenue$11.0M2%

Related Comparisons